Educational research tool. Not investment advice. You are responsible for your own trading decisions.

Verdix.
← All analysis

Broadcom Inc. (AVGO)

Verdict history · AVGO

Every call Verdix has made on AVGO.

While a verdict holds, its return keeps accumulating from the day the call was made — it resets only when the verdict itself changes.

See methodology for how verdicts are produced. Full track record →

Why the panel isn’t ready to call AVGO yet — and where they disagree.

WaitMEDIUM confidence

A quality business, but not at today's price — the panel is waiting for a better price or a catalyst.

NASDAQ · Information Technology / Semiconductors & Infrastructure Software · 2026-08-15 · analysis, not advice

Key levels and fundamentals figures are sourced from public market data and filings. All panel verdicts, archetype reasoning, and synthesis are AI-generated analysis.

Verdict

Wait

MEDIUM confidence

Why

Six investing archetypes dissect Broadcom at $393: everyone agrees the AI-infrastructure moat is real, but five of six say the price embeds too much optimism with too little margin of safety. The debate hangs on whether to buy the dip at the $386–$388 technical fulcrum or wait for a cheaper entry after the September 2 earnings call.

Level to watch

Key support 388

−1.3% from 392.99

Next catalyst

Trigger to confirm the breakout: A weekly close above $414.61 with weekly MACD histogram turning positive and RSI above 55 would confirm the bull flag and target a retest of the $495 all-time high.

The panel's take

Verdict: WAIT · Conviction: MED · Last price: 392.99

This is a textbook BUY-vs-WAIT split. The bulls (The Scuttlebutt Growth Investor, The GARP Operator) and the cautious camp (Technical Scout, The Intrinsic-Value Modeler, The Moat Compounder, The Forensic Skeptic, The Macro Opportunist) all agree AVGO is a wonderful business; the disagreement is solely about whether today's $393 price offers a margin of safety. Every cautious voice says "great company, wrong price/timing" — pure PRICE/TIMING objections. With a specific, identified trigger (the $386–$388 confluence zone resolving, plus September 2 earnings), and price being the single blocker, this routes to WAIT, not BALANCED.

Key levels

Key levels · AVGO

USD · as of 2026-08-15
Analyst consensus 392.99
R3495
+26.0%
R2444.7
+13.2%
R1414.61
+5.5%
S1386
−1.8%
S2388
−1.3%
S3363
−7.6%
NOW
392.99

Analyst consensus target 392.99 USD · range 392.99392.99

Key support & resistance and analyst consensus — educational analysis, not advice. These are not entry or exit prices. Trading involves risk of loss.

What legendary investors think

We ran Broadcom Inc. past a panel of 6 legendary investors' frameworks.

The panel · 6 investors

🟢
1
Bullish
5
Neutral
🔴
0
Bearish
The Intrinsic-Value ModelerValuation/DCF NeutralMed

Signal: A discounted cash flow model—anchored on a 22% blended revenue CAGR stepping down to 12% over five years and a 42% terminal operating margin—lands intrinsic value at roughly $420, just 7% above today’s $393, which means the market is already discounting a bullish base case with no margin for error. Conviction: Conviction is held back because the entire valuation hangs on one unresolved assumption: that AI capex continues at a blistering pace for several more years—any slowdown, and the stock re-rates sharply below $400.

The GARP OperatorGrowth (GARP) NeutralMed

Signal: A forward P/E of 22.6 paired with estimated 20% EPS growth yields a PEG ratio near 1.1, and 25 upward analyst revisions versus 9 downward in the last 30 days signal that the order book has genuine momentum heading into the September earnings call. Conviction: Until the $386–$388 support confluence proves it can hold on a weekly close, conviction stays capped; the bearish weekly MACD crossover makes the current price a bridge too far for new money.

The Scuttlebutt Growth InvestorGrowth/Management🟢 BullishHigh

Signal: The company scores a clean 15 out of 15 on the 15-point checklist—custom ASIC designs co-developed with hyperscalers create switching costs that competitors openly admit are the hardest to displace in data-center silicon—and the VMware integration is already spawning new private-AI cloud bundles that extend the ecosystem lock-in. Conviction: The one factor that keeps conviction from being absolute is the 30-million-share sale by the co-founder; if insider selling persists without a clear diversification rationale, the thesis needs a second look.

The Moat CompounderValue/Quality/Moat NeutralMed

Signal: A 68% gross margin and a 28.4% ROE confirm genuine pricing power, and the moat is widening because VMware’s recurring-revenue software layer creates switching costs on top of already-sticky custom silicon relationships. Conviction: Conviction is weak at this price because the trailing P/E of roughly 65 times offers no margin of safety; wonderful business, but the entry demands a 25–40% discount to intrinsic value that simply is not here.

The Forensic SkepticContrarian/Forensic NeutralLow

Signal: Net debt sits at $45 billion against an enterprise value near $1.9 trillion, and insiders sold 6,328% more shares than they bought over three months—including 30.2 million shares dumped by the co-founder in a single day—while 28 of 32 analysts rate the stock a Buy and zero say Sell. Conviction: Sentiment euphoria paired with a 69-times trailing P/E means any disappointment in AI spending or VMware renewal rates could trigger violent multiple compression; conviction stays low until the price offers a genuine margin of safety closer to $300.

The Macro OpportunistMacro/Timing NeutralLow

Signal: Four independent technical constructs—the weekly EMA20, weekly Fib 50%, monthly Fib 23.6%, and a weekly horizontal level—converge at $386–$388 to form a battleground zone that will likely determine whether the Stage 2 uptrend resumes or the correction extends to $354. Conviction: The weekly MACD’s bearish crossover is expanding while the monthly MACD histogram hovers near zero, so conviction is held back by the unresolved tug-of-war between a firm monthly trend and deteriorating weekly momentum.

Each view is one investing framework applied to the stock — a perspective, not advice, and identical for every reader. Signals are the panel's own scale, not a recommendation to act.

Where they agree — and where they clash

Common ground

  • All six personas agree AVGO is a high-quality business. The moat—built on custom AI ASICs, networking silicon, and VMware’s recurring-revenue software—is genuinely wide, with 68% gross margins and 28%+ ROE attesting to durable competitive advantages.
  • Everyone acknowledges the AI infrastructure tailwind is secular, not cyclical. Hyperscaler custom-chip roadmaps and VMware’s enterprise lock-in support multi-year revenue compounding.
  • No persona sees a reason to sell the business itself. The debate is exclusively about price and entry timing: every cautious voice says “great company, wrong price.”
  • All point to the September 2 earnings call as a pivotal catalyst. The market is flying blind on forward guidance, and Hock Tan’s commentary will either validate the growth trajectory or trigger a re-rating.
  • The $386–$388 zone is universally recognized as the near-term technical fulcrum—break it and the correction deepens; hold it and the bull case regains footing.

The real debate

The question it comes down to: Does the $386–$388 confluence zone hold on a weekly close and does the September 2 earnings call confirm that AI hyperscaler spending is still accelerating—or is the market already pricing in years of flawless execution that leaves no room for even a modest stumble?

The bottom line

  • Trigger to confirm the breakout: A weekly close above $414.61 with weekly MACD histogram turning positive and RSI above 55 would confirm the bull flag and target a retest of the $495 all-time high.
  • The price where value emerges: A pullback into the $340–$360 range compresses the forward P/E to roughly 18–20×, creating a margin of safety that would convert several cautious archetypes to buyers.
  • Next catalyst: The September 2 earnings report—specifically Hock Tan’s forward guidance on AI ASIC demand and VMware subscription conversion rates—will either validate the 25%+ growth trajectory or puncture the premium valuation.
  • Risk to monitor: Any signal from a major hyperscaler (Microsoft, Google, Meta, Amazon) that AI capex plans are plateauing would undercut the entire growth narrative and likely compress the multiple toward 15–20× normalized earnings.
  • Further out: If VMware license-renewal data reveals churn or the co-founder’s insider selling accelerates beyond the disclosed 30.2 million shares, the “wonderful business” consensus could fracture on management-alignment concerns.

contact@verdixhq.com · Published 2026-08-15 · Prices as of 2026-08-15 · Time horizon: 3–12 months · No direct position held in AVGO · AVGO verdict history → · Methodology →

Verdix's panel is made up of AI archetypes that apply the well-documented, publicly known investment frameworks of famous investors. They are AI agents — not the investors themselves. Verdix is not affiliated with, endorsed by, or authorized by any real individual, and the archetypes do not represent any real person's actual views, holdings, or statements. Every verdict is AI-generated.

Verdix provides educational equity research and AI-generated multi-perspective analysis. Nothing here constitutes personalized investment advice or a recommendation to buy or sell any security. Verdicts are uniform across all users and do not consider your individual financial situation, risk tolerance, or objectives. Trading and investing involve substantial risk of loss. Past performance does not predict future results. Consult a licensed financial advisor before making investment decisions.

Stay ahead of AVGO's next verdict

The panel's view can flip on new earnings, a guidance cut, or a valuation shift. Get the update the moment it happens — not weeks later.

One email, only on a verdict change. Unsubscribe anytime.